Clinicopathological predictors of overall survival in uni- and multivariable analysis
| . | Univariable analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR* . | 95% c.i. . | P value . | HR* . | 95% c.i. . | P value† . | |
| Age | 1.02 | 1.00–1.03 | 0.049 | 1.03 | 1.01–1.05 | <0.001 |
| Sex (female) | 1.23 | 0.61–1.09 | 0.160 | |||
| Tumour location (tail) | 0.75 | 0.50–1.14 | 0.179 | |||
| Neoadjuvant therapy | 0.73 | 0.23–2.30 | 0.597 | |||
| Tumour diameter | 1.11 | 1.01–1.22 | 0.029 | |||
| Margin status (R1) | 1.60 | 1.20–2.14 | 0.001 | 1.52 | 1.12–2.08 | 0.007 |
| Differentiation grade (poor) | 1.61 | 1.21–2.15 | 0.002 | 1.70 | 1.25–2.31 | <0.001 |
| Perineural growth | 1.49 | 1.03–2.15 | 0.034 | 1.61 | 1.07–2.42 | 0.022 |
| Lymphovascular invasion | 1.59 | 1.19–2.12 | 0.002 | 1.35 | 0.97–1.88 | 0.078 |
| Lymph node ratio | 2.99 | 1.67–5.35 | <0.001 | 3.30 | 3.30–6.45 | <0.001 |
| Adjuvant therapy | 0.75 | 0.54–1.05 | 0.097 | 0.66 | 0.45–0.96 | 0.031 |
| Molecular subtype (basal-like) | 1.49 | 1.03–2.15 | 0.035 | 1.49 | 1.01–2.19 | 0.045 |
| . | Univariable analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR* . | 95% c.i. . | P value . | HR* . | 95% c.i. . | P value† . | |
| Age | 1.02 | 1.00–1.03 | 0.049 | 1.03 | 1.01–1.05 | <0.001 |
| Sex (female) | 1.23 | 0.61–1.09 | 0.160 | |||
| Tumour location (tail) | 0.75 | 0.50–1.14 | 0.179 | |||
| Neoadjuvant therapy | 0.73 | 0.23–2.30 | 0.597 | |||
| Tumour diameter | 1.11 | 1.01–1.22 | 0.029 | |||
| Margin status (R1) | 1.60 | 1.20–2.14 | 0.001 | 1.52 | 1.12–2.08 | 0.007 |
| Differentiation grade (poor) | 1.61 | 1.21–2.15 | 0.002 | 1.70 | 1.25–2.31 | <0.001 |
| Perineural growth | 1.49 | 1.03–2.15 | 0.034 | 1.61 | 1.07–2.42 | 0.022 |
| Lymphovascular invasion | 1.59 | 1.19–2.12 | 0.002 | 1.35 | 0.97–1.88 | 0.078 |
| Lymph node ratio | 2.99 | 1.67–5.35 | <0.001 | 3.30 | 3.30–6.45 | <0.001 |
| Adjuvant therapy | 0.75 | 0.54–1.05 | 0.097 | 0.66 | 0.45–0.96 | 0.031 |
| Molecular subtype (basal-like) | 1.49 | 1.03–2.15 | 0.035 | 1.49 | 1.01–2.19 | 0.045 |
*Hazard ratios in Cox regression analyses on survival. †Analysed in 191 complete cases via multivariable Cox regression analysis with backward selection until predictors with a P value <0.10 remained.
Clinicopathological predictors of overall survival in uni- and multivariable analysis
| . | Univariable analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR* . | 95% c.i. . | P value . | HR* . | 95% c.i. . | P value† . | |
| Age | 1.02 | 1.00–1.03 | 0.049 | 1.03 | 1.01–1.05 | <0.001 |
| Sex (female) | 1.23 | 0.61–1.09 | 0.160 | |||
| Tumour location (tail) | 0.75 | 0.50–1.14 | 0.179 | |||
| Neoadjuvant therapy | 0.73 | 0.23–2.30 | 0.597 | |||
| Tumour diameter | 1.11 | 1.01–1.22 | 0.029 | |||
| Margin status (R1) | 1.60 | 1.20–2.14 | 0.001 | 1.52 | 1.12–2.08 | 0.007 |
| Differentiation grade (poor) | 1.61 | 1.21–2.15 | 0.002 | 1.70 | 1.25–2.31 | <0.001 |
| Perineural growth | 1.49 | 1.03–2.15 | 0.034 | 1.61 | 1.07–2.42 | 0.022 |
| Lymphovascular invasion | 1.59 | 1.19–2.12 | 0.002 | 1.35 | 0.97–1.88 | 0.078 |
| Lymph node ratio | 2.99 | 1.67–5.35 | <0.001 | 3.30 | 3.30–6.45 | <0.001 |
| Adjuvant therapy | 0.75 | 0.54–1.05 | 0.097 | 0.66 | 0.45–0.96 | 0.031 |
| Molecular subtype (basal-like) | 1.49 | 1.03–2.15 | 0.035 | 1.49 | 1.01–2.19 | 0.045 |
| . | Univariable analysis . | Multivariable analysis . | ||||
|---|---|---|---|---|---|---|
| HR* . | 95% c.i. . | P value . | HR* . | 95% c.i. . | P value† . | |
| Age | 1.02 | 1.00–1.03 | 0.049 | 1.03 | 1.01–1.05 | <0.001 |
| Sex (female) | 1.23 | 0.61–1.09 | 0.160 | |||
| Tumour location (tail) | 0.75 | 0.50–1.14 | 0.179 | |||
| Neoadjuvant therapy | 0.73 | 0.23–2.30 | 0.597 | |||
| Tumour diameter | 1.11 | 1.01–1.22 | 0.029 | |||
| Margin status (R1) | 1.60 | 1.20–2.14 | 0.001 | 1.52 | 1.12–2.08 | 0.007 |
| Differentiation grade (poor) | 1.61 | 1.21–2.15 | 0.002 | 1.70 | 1.25–2.31 | <0.001 |
| Perineural growth | 1.49 | 1.03–2.15 | 0.034 | 1.61 | 1.07–2.42 | 0.022 |
| Lymphovascular invasion | 1.59 | 1.19–2.12 | 0.002 | 1.35 | 0.97–1.88 | 0.078 |
| Lymph node ratio | 2.99 | 1.67–5.35 | <0.001 | 3.30 | 3.30–6.45 | <0.001 |
| Adjuvant therapy | 0.75 | 0.54–1.05 | 0.097 | 0.66 | 0.45–0.96 | 0.031 |
| Molecular subtype (basal-like) | 1.49 | 1.03–2.15 | 0.035 | 1.49 | 1.01–2.19 | 0.045 |
*Hazard ratios in Cox regression analyses on survival. †Analysed in 191 complete cases via multivariable Cox regression analysis with backward selection until predictors with a P value <0.10 remained.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
